Moreover, we show that MAP3K3 inhibition, achieved through RNAi-mediated knockdown or pharmacological means, overcomes CDK4/6 inhibitor resistance in luminal breast cancer cells. This evidence concerns the gene CDK4 and breast carcinoma.